All In Biotech

Drug Trial Radar · NCT07373457

A Phase I Study of HW201877 in Healthy Subjects

A Single-Center, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dosing, Dose-escalation, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, PK/PD, Food Effect of HW201877 in Healthy Volunteers.

Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 104 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

104

Planned (sponsor's estimate)

Start

Jun 26, 2025

Primary completion

Mar 2026

Study completion Mar 2026

Sponsor

Sponsor type
Industry
First posted
Jan 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase I, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and food effect (FE) of HW201877 in healthy subjects following (1) a single ascending dose (Part 1), which includes a single-dose, two-period crossover FE cohort; (2) a multiple ascending dose (Part 2).

Conditions

  • Healthy Participants
  • IBD (Inflammatory Bowel Disease)

Interventions

  • HW201877 capsulesDrug

    Dose 1 to Dose 7

  • PlaceboDrug

    Dose 1 to Dose 7

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number and severity of treatment emergent adverse events (TEAEs)Time frame: Day 1 to Day 5

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Hospital of Jilin University

    Changchun, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.